Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

682 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M. Sgroi DC, et al. Among authors: cuzick j. Lancet Oncol. 2013 Oct;14(11):1067-1076. doi: 10.1016/S1470-2045(13)70387-5. Epub 2013 Sep 12. Lancet Oncol. 2013. PMID: 24035531 Free PMC article. Clinical Trial.
Adjuvant use of anastrozole in breast cancer.
Cuzick J, Buzdar A, Baum M, Bianco R, Coleman R, Constenla M, Distler W, Dowsett M, Forbes J, Guastalla JP, Houghton J, Williams N, Howell A, Locker G, MacKey J, Sainsbury R, Tobias J. Cuzick J, et al. J Clin Oncol. 2004 Apr 15;22(8):1524-6; author reply 1526-7. doi: 10.1200/JCO.2004.99.165. J Clin Oncol. 2004. PMID: 15084628 No abstract available.
Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model.
Santen RJ, Boyd NF, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, Easton D, Forbes JF, Key T, Hankinson SE, Howell A, Ingle J; Breast Cancer Prevention Collaborative Group. Santen RJ, et al. Among authors: cuzick j. Endocr Relat Cancer. 2007 Jun;14(2):169-87. doi: 10.1677/ERC-06-0045. Endocr Relat Cancer. 2007. PMID: 17639036 Review.
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group; Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, et al. Among authors: cuzick j. Lancet Oncol. 2008 Jan;9(1):45-53. doi: 10.1016/S1470-2045(07)70385-6. Lancet Oncol. 2008. PMID: 18083636 Clinical Trial.
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A. Dowsett M, et al. Among authors: cuzick j. J Clin Oncol. 2008 Mar 1;26(7):1059-65. doi: 10.1200/JCO.2007.12.9437. Epub 2008 Jan 28. J Clin Oncol. 2008. PMID: 18227529 Clinical Trial.
682 results